| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0091270011415528 |
| P698 | PubMed publication ID | 22232759 |
| P2093 | author name string | Lei Zhang | |
| Ping Zhao | |||
| Pengfei Song | |||
| Eva Gil Berglund | |||
| Shiew-Mei Huang | |||
| Darrell R Abernethy | |||
| Yuichi Sugiyama | |||
| Vikram Arya | |||
| K Sandy Pang | |||
| Lawrence J Lesko | |||
| Kellie S Reynolds | |||
| Joseph A Grillo | |||
| Jenny H Zheng | |||
| Arthur J Atkinson | |||
| Manuela de L T Vieira | |||
| Ta-Chen Wu | |||
| P2860 | cites work | Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance | Q44804450 |
| Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism | Q46111551 | ||
| Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. | Q46461608 | ||
| Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions | Q48567088 | ||
| Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment. | Q51790803 | ||
| Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. | Q51917380 | ||
| Development and evaluation of a generic physiologically based pharmacokinetic model for children. | Q51933198 | ||
| Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. | Q51975107 | ||
| Simulation and prediction of in vivo drug metabolism in human populations from in vitro data | Q28286115 | ||
| The Simcyp population-based ADME simulator | Q28308225 | ||
| Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil | Q28362294 | ||
| Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers | Q33185413 | ||
| A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance | Q33532744 | ||
| Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children | Q33998916 | ||
| Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality | Q34117094 | ||
| Cyclosporine markedly raises the plasma concentrations of repaglinide | Q34561434 | ||
| Prediction of intestinal first-pass drug metabolism | Q34708855 | ||
| Hepatic drug metabolism and transport in patients with kidney disease. | Q35569537 | ||
| Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial | Q36240746 | ||
| Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections | Q36292382 | ||
| Emerging evidence of the impact of kidney disease on drug metabolism and transport | Q37128651 | ||
| Altered nonrenal drug clearance in ESRD. | Q37305305 | ||
| A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn | Q37404434 | ||
| Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters | Q37696476 | ||
| Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science | Q37790383 | ||
| Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans | Q37808376 | ||
| Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review | Q37824590 | ||
| The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil | Q41817750 | ||
| Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil | Q41822316 | ||
| The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. | Q42284377 | ||
| Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on th | Q43212778 | ||
| Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis | Q43812136 | ||
| Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment | Q44770176 | ||
| P433 | issue | 1 Suppl | |
| P921 | main subject | pharmacokinetics | Q323936 |
| chronic renal insufficiency | Q736715 | ||
| P304 | page(s) | 91S-108S | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. | |
| P478 | volume | 52 |
| Q30491777 | A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions |
| Q34099766 | Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients |
| Q38056878 | Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption |
| Q52318495 | Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. |
| Q92854569 | Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure |
| Q52601551 | Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mech |
| Q38110809 | Do children have the same vulnerability to metabolic drug–drug interactions as adults? A critical analysis of the literature |
| Q36910606 | Dose selection based on physiologically based pharmacokinetic (PBPK) approaches |
| Q38287050 | Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease |
| Q42608257 | Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model |
| Q39645850 | From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example |
| Q38578341 | In silico ADME/T modelling for rational drug design. |
| Q86067835 | Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure |
| Q26775949 | Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer |
| Q39212609 | Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide |
| Q38075057 | Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. |
| Q38188035 | Model-based clinical drug development in the past, present and future: a commentary |
| Q99724613 | Novel Mechanistic PBPK Model to Predict Renal Clearance in Varying Stages of CKD by Incorporating Tubular Adaptation and Dynamic Passive Reabsorption |
| Q37986722 | PBPK as a tool in regulatory review |
| Q28066513 | PBPK modeling and simulation in drug research and development |
| Q41819424 | Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative |
| Q57684574 | Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions |
| Q28088352 | Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification |
| Q58073610 | Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective |
| Q38014312 | Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology |
| Q38959281 | Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine |
| Q39643626 | Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor |
| Q38087695 | Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach |
| Q39240124 | Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions |
| Q85791328 | Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model |
| Q37121662 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. |
| Q45815953 | Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease |
| Q40072776 | Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. |
| Q38844656 | The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives |
| Q53233045 | The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance. |
| Q37982653 | The role of physiologically based pharmacokinetic modeling in regulatory review |
| Q34502721 | The simcyp population based simulator: architecture, implementation, and quality assurance |
| Q27020967 | Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations |
| Q53630136 | Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling. |
| Q90737007 | Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates |
| Q38812692 | Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine |
| Q37978192 | Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. |
Search more.